Equities research analysts predict that NuVasive, Inc. (NASDAQ:NUVA) will post $0.56 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for NuVasive’s earnings, with the highest EPS estimate coming in at $0.57 and the lowest estimate coming in at $0.55. NuVasive reported earnings per share of $0.53 in the same quarter last year, which indicates a positive year over year growth rate of 5.7%. The company is expected to issue its next earnings report on Thursday, February 8th.
On average, analysts expect that NuVasive will report full-year earnings of $1.91 per share for the current financial year, with EPS estimates ranging from $1.90 to $1.92. For the next financial year, analysts anticipate that the firm will post earnings of $2.30 per share, with EPS estimates ranging from $2.19 to $2.53. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for NuVasive.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Tuesday, October 24th. The medical device company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.04. The company had revenue of $247.40 million for the quarter, compared to analyst estimates of $255.70 million. NuVasive had a net margin of 6.36% and a return on equity of 13.65%. NuVasive’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.40 earnings per share.
Several institutional investors and hedge funds have recently modified their holdings of NUVA. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock worth $146,000 after purchasing an additional 158 shares in the last quarter. Howard Hughes Medical Institute boosted its position in shares of NuVasive by 82.8% during the second quarter. Howard Hughes Medical Institute now owns 2,066 shares of the medical device company’s stock valued at $159,000 after buying an additional 936 shares during the last quarter. Zions Bancorporation bought a new stake in shares of NuVasive in the third quarter valued at $160,000. Shelton Capital Management bought a new stake in shares of NuVasive in the second quarter valued at $221,000. Finally, Verition Fund Management LLC bought a new stake in shares of NuVasive in the second quarter valued at $233,000.
Shares of NuVasive (NASDAQ:NUVA) opened at $60.77 on Thursday. The company has a quick ratio of 1.51, a current ratio of 2.85 and a debt-to-equity ratio of 0.76. The firm has a market cap of $3,100.00, a PE ratio of 51.07, a PEG ratio of 1.56 and a beta of 0.77. NuVasive has a fifty-two week low of $49.25 and a fifty-two week high of $81.68.
NuVasive announced that its board has initiated a stock repurchase program on Tuesday, October 24th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the medical device company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “$0.56 Earnings Per Share Expected for NuVasive, Inc. (NUVA) This Quarter” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/04/0-56-earnings-per-share-expected-for-nuvasive-inc-nuva-this-quarter-2.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.